Evidence map›Paper›PMID 28694457›Full record

ArticleScientific reports2017

Characterisation of preproendothelin-1 derived peptides identifies Endothelin-Like Domain Peptide as a modulator of Endothelin-1.

Jale Yuzugulen, Julie A Douthwaite, Elizabeth G Wood, Inmaculada C Villar, Nimesh S A Patel, James Jegard, Hubert Gaertner, Irène Rossitto-Borlat, Keith Rose, Oliver Hartley and 3 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.3field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Endothelin 2: a key player in ovulation and fertility.Reproduction (Cambridge, England) · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 2 countries.

Jale YuzugulenWilliam Harvey Research Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, EC1M 6BQ, UK.
Julie A DouthwaiteWilliam Harvey Research Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, EC1M 6BQ, UK.
Elizabeth G WoodWilliam Harvey Research Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, EC1M 6BQ, UK.
Inmaculada C VillarWilliam Harvey Research Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, EC1M 6BQ, UK.ORCID 0000-0001-8689-4655
Nimesh S A PatelWilliam Harvey Research Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, EC1M 6BQ, UK.
James JegardWilliam Harvey Research Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, EC1M 6BQ, UK.
Hubert GaertnerFaculty of Medicine, University of Geneva, 1211, Geneva 4, Switzerland.
Irène Rossitto-BorlatFaculty of Medicine, University of Geneva, 1211, Geneva 4, Switzerland.
Keith RoseFaculty of Medicine, University of Geneva, 1211, Geneva 4, Switzerland.
Oliver HartleyFaculty of Medicine, University of Geneva, 1211, Geneva 4, Switzerland.
Pedro R CutillasBarts Cancer Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, EC1M 6BQ, UK.ORCID 0000-0002-3426-2274
Amrita AhluwaliaWilliam Harvey Research Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, EC1M 6BQ, UK.
Roger CorderWilliam Harvey Research Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, EC1M 6BQ, UK. r.corder@qmul.ac.uk.ORCID 0000-0003-1712-6841
Queen Mary University of London · GBUniversity of Geneva · CH

Funding

Biotechnology and Biological Sciences Research Council BB/M006174/1Medical Research Council G0801509
6 · The paper itself

Abstract

Endothelin-1 (ET-1) is involved in the pathogenesis of cardiac and renal diseases, and in the progression of tumour growth in cancer, but current diagnosis and treatment remain inadequate. Peptides derived from the 212 amino acid precursor preproendothelin-1 (ppET-1) may have utility as biomarkers, or cause biological effects that are unaffected by endothelin receptor antagonists. Here, we used specific immunoassays and LC-MS/MS to identify NT-proET-1 (ppET-1

Indexed as

A549 CellsBiomarkersCell LineChromatography, LiquidCulture Media, ConditionedEndothelial CellsEndothelin-1Heart FailureHumansInjections, IntravenousPeptide FragmentsProtein PrecursorsTandem Mass SpectrometryBiomarkersCulture Media, ConditionedEndothelin-1Peptide Fragmentsproendothelin 1Protein Precursors

Identifiers

PMID28694457
PMCPMC5503984
OpenAlexW2728007050

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.